Verrica Pharmaceuticals Inc (VRCA) - Total Liabilities
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has total liabilities worth $22.73 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Verrica Pharmaceuticals Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Verrica Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See VRCA working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Verrica Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Balyo SA
PA:BALYO
|
France | €34.75 Million |
|
Multicampus Corporation
KQ:067280
|
Korea | ₩84.43 Billion |
|
Ctek AB
ST:CTEK
|
Sweden | Skr621.40 Million |
|
WMG Holdings Bhd
KLSE:6378
|
Malaysia | RM170.29 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩238.27 Billion |
|
Kingwaytek Technology Co Ltd
TWO:6516
|
Taiwan | NT$261.79 Million |
|
Patria Bank SA
RO:PBK
|
Romania | RON5.09 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Verrica Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Verrica Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verrica Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verrica Pharmaceuticals Inc (2016–2025)
The table below shows the annual total liabilities of Verrica Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $22.39 Million | -65.02% |
| 2024-12-31 | $63.99 Million | +3.49% |
| 2023-12-31 | $61.83 Million | +1218.98% |
| 2022-12-31 | $4.69 Million | -90.13% |
| 2021-12-31 | $47.52 Million | +15.43% |
| 2020-12-31 | $41.17 Million | +1107.63% |
| 2019-12-31 | $3.41 Million | +37.63% |
| 2018-12-31 | $2.48 Million | -84.64% |
| 2017-12-31 | $16.12 Million | +402.62% |
| 2016-12-31 | $3.21 Million | -- |
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more